Loading organizations...
venture capital firm investing in early-stage healthcare and biotechnology innovations, from pre-seed to growth capital.
Get email updates
Join 25K+ founders & VCs who start their week informed.
Kurma Partners is a venture capital firm based in Paris, France, with operations in Munich, Germany, investing in early-stage healthcare and biotechnology innovations. The firm focuses on company creation and development across biopharmaceuticals, diagnostics, and digital health, managing approximately €890 million across its funds. With a portfolio of around 60 companies, Kurma Partners has made 91 investments totaling $582 million, supporting 1,400 employees across its financed ventures. Led by Managing Partners Thierry Laugel and Rémi Droller, with Peter Neubeck overseeing Munich operations, the firm became fully integrated into Eurazeo as of April 2025. Notable early investments include Zealand Pharma, reflecting its strategy of collaborating with European academic researchers. Kurma Partners was founded in 2009 by Thierry Laugel. Its business model centers on raises funds through dedicated biofunds for investing in healthcare startups, fully integrated into Eurazeo since 2025, which provides strategic cornerstone investment.
Key people at Kurma Partners.
Kurma Partners is a leading European venture capital firm specializing in healthcare and biotechnology investments, managing approximately €470-600 million in assets. The firm operates two main investment franchises: Kurma Biofund, which focuses on therapeutic innovations, and Kurma Diagnostics, which targets diagnostics and digital health technologies. Kurma Partners aims to transform cutting-edge academic research into innovative medicines and medical devices addressing severe diseases with high unmet medical needs. Their investment philosophy centers on early-stage funding to accelerate scientific discoveries into viable healthcare solutions, significantly impacting the European startup ecosystem in life sciences by supporting over 40 companies to date[1][2][3][5].
Founded in 2009 and headquartered in Paris with an office in Munich, Kurma Partners was established to bridge the gap between academic research and commercial healthcare innovation. The firm was founded by key partners including Alain Horvais and Amanda Gett Chaperot, among others, who brought expertise in life sciences and venture capital. Over time, Kurma Partners has evolved to focus exclusively on early-stage investments in life sciences, building a strong network with top European academic institutions to source disruptive scientific discoveries. This strategic focus has allowed Kurma to develop a specialized investment approach and build a robust portfolio in biotechnology and medical innovation[3][4].
Kurma Partners is riding the global trend of increased investment in healthcare innovation driven by advances in biotechnology, digital health, and diagnostics. The timing is favorable due to growing demand for novel therapies addressing complex diseases and the digitization of healthcare. Market forces such as aging populations, regulatory support for innovation, and expanding healthcare budgets in Europe work in Kurma’s favor. By funding early-stage companies that translate academic research into practical healthcare solutions, Kurma influences the broader ecosystem by fostering innovation pipelines, enabling technology transfer, and strengthening Europe’s position in global life sciences[2][3].
Looking ahead, Kurma Partners is well-positioned to capitalize on emerging trends such as personalized medicine, AI-driven diagnostics, and novel therapeutic modalities. Their continued focus on early-stage investments and strong academic collaborations will likely enhance their influence in shaping the future of healthcare innovation in Europe. As the life sciences sector evolves with new scientific breakthroughs and digital transformation, Kurma’s role as a specialized investor and ecosystem builder is expected to grow, potentially expanding their fund size and portfolio diversity while maintaining their high standards of scientific rigor and impact[1][3][5].
Key people at Kurma Partners.
Kurma Partners has more than 26 tracked investments across 24 companies. The latest tracked deal is $636.0M Seed Extension in Laigo Bio in March 2026.